KYMERA THERAPEUTICS INC (KYMR) Stock Fundamental Analysis

NASDAQ:KYMR • US5015751044

85.11 USD
+0.27 (+0.32%)
At close: Feb 18, 2026
84.31 USD
-0.8 (-0.94%)
After Hours: 2/18/2026, 4:50:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to KYMR. KYMR was compared to 521 industry peers in the Biotechnology industry. While KYMR seems to be doing ok healthwise, there are quite some concerns on its profitability. KYMR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • KYMR had negative earnings in the past year.
  • In the past year KYMR has reported a negative cash flow from operations.
  • In the past 5 years KYMR always reported negative net income.
  • KYMR had negative operating cash flow in 4 of the past 5 years.
KYMR Yearly Net Income VS EBIT VS OCF VS FCFKYMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

  • KYMR has a Return On Assets of -26.78%. This is in the better half of the industry: KYMR outperforms 69.10% of its industry peers.
  • The Return On Equity of KYMR (-31.19%) is better than 75.24% of its industry peers.
Industry RankSector Rank
ROA -26.78%
ROE -31.19%
ROIC N/A
ROA(3y)-24.69%
ROA(5y)-20.37%
ROE(3y)-31.86%
ROE(5y)-27.33%
ROIC(3y)N/A
ROIC(5y)N/A
KYMR Yearly ROA, ROE, ROICKYMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KYMR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYMR Yearly Profit, Operating, Gross MarginsKYMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • KYMR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for KYMR has been increased compared to 1 year ago.
  • The number of shares outstanding for KYMR has been increased compared to 5 years ago.
  • Compared to 1 year ago, KYMR has an improved debt to assets ratio.
KYMR Yearly Shares OutstandingKYMR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KYMR Yearly Total Debt VS Total AssetsKYMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • KYMR has an Altman-Z score of 24.38. This indicates that KYMR is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of KYMR (24.38) is better than 90.98% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that KYMR is not too dependend on debt financing.
  • KYMR has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: KYMR outperforms 50.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 24.38
ROIC/WACCN/A
WACC8.69%
KYMR Yearly LT Debt VS Equity VS FCFKYMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 7.38 indicates that KYMR has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 7.38, KYMR is doing good in the industry, outperforming 72.17% of the companies in the same industry.
  • A Quick Ratio of 7.38 indicates that KYMR has no problem at all paying its short term obligations.
  • KYMR has a Quick ratio of 7.38. This is in the better half of the industry: KYMR outperforms 72.17% of its industry peers.
Industry RankSector Rank
Current Ratio 7.38
Quick Ratio 7.38
KYMR Yearly Current Assets VS Current LiabilitesKYMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for KYMR have decreased strongly by -58.15% in the last year.
  • The Revenue for KYMR has decreased by -50.05% in the past year. This is quite bad
  • KYMR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 74.25% yearly.
EPS 1Y (TTM)-58.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.63%
Revenue 1Y (TTM)-50.05%
Revenue growth 3Y-13.54%
Revenue growth 5Y74.25%
Sales Q2Q%-26.12%

3.2 Future

  • Based on estimates for the next years, KYMR will show a decrease in Earnings Per Share. The EPS will decrease by -8.11% on average per year.
  • KYMR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.36% yearly.
EPS Next Y-24.11%
EPS Next 2Y-15.38%
EPS Next 3Y-12.59%
EPS Next 5Y-8.11%
Revenue Next Year6.85%
Revenue Next 2Y-2.94%
Revenue Next 3Y-1.28%
Revenue Next 5Y-1.36%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
KYMR Yearly Revenue VS EstimatesKYMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
KYMR Yearly EPS VS EstimatesKYMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • KYMR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KYMR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYMR Price Earnings VS Forward Price EarningsKYMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYMR Per share dataKYMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as KYMR's earnings are expected to decrease with -12.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.38%
EPS Next 3Y-12.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for KYMR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KYMERA THERAPEUTICS INC

NASDAQ:KYMR (2/18/2026, 4:50:42 PM)

After market: 84.31 -0.8 (-0.94%)

85.11

+0.27 (+0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-19
Inst Owners106.53%
Inst Owner Change1.24%
Ins Owners1.29%
Ins Owner Change0.62%
Market Cap6.79B
Revenue(TTM)43.73M
Net Income(TTM)-295.12M
Analysts86.21
Price Target114.77 (34.85%)
Short Float %12.06%
Short Ratio8.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.81%
Min EPS beat(2)-14.98%
Max EPS beat(2)-14.63%
EPS beat(4)1
Avg EPS beat(4)-7.19%
Min EPS beat(4)-14.98%
Max EPS beat(4)12.26%
EPS beat(8)5
Avg EPS beat(8)6.01%
EPS beat(12)6
Avg EPS beat(12)1.09%
EPS beat(16)6
Avg EPS beat(16)-3.08%
Revenue beat(2)0
Avg Revenue beat(2)-68.8%
Min Revenue beat(2)-85.7%
Max Revenue beat(2)-51.89%
Revenue beat(4)1
Avg Revenue beat(4)-15.73%
Min Revenue beat(4)-85.7%
Max Revenue beat(4)113.36%
Revenue beat(8)3
Avg Revenue beat(8)-5.2%
Revenue beat(12)4
Avg Revenue beat(12)-13.21%
Revenue beat(16)4
Avg Revenue beat(16)-18.16%
PT rev (1m)2.68%
PT rev (3m)64.44%
EPS NQ rev (1m)-2.87%
EPS NQ rev (3m)0.52%
EPS NY rev (1m)-1.5%
EPS NY rev (3m)-3.66%
Revenue NQ rev (1m)-1.19%
Revenue NQ rev (3m)-6.51%
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-26.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 155.28
P/FCF N/A
P/OCF N/A
P/B 7.18
P/tB 7.18
EV/EBITDA N/A
EPS(TTM)-3.59
EYN/A
EPS(NY)-3.86
Fwd EYN/A
FCF(TTM)-2.89
FCFYN/A
OCF(TTM)-2.86
OCFYN/A
SpS0.55
BVpS11.86
TBVpS11.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.78%
ROE -31.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.69%
ROA(5y)-20.37%
ROE(3y)-31.86%
ROE(5y)-27.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.56%
Cap/Sales 5.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.38
Quick Ratio 7.38
Altman-Z 24.38
F-Score2
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)412.2%
Cap/Depr(5y)364.06%
Cap/Sales(3y)25.74%
Cap/Sales(5y)21.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.63%
EPS Next Y-24.11%
EPS Next 2Y-15.38%
EPS Next 3Y-12.59%
EPS Next 5Y-8.11%
Revenue 1Y (TTM)-50.05%
Revenue growth 3Y-13.54%
Revenue growth 5Y74.25%
Sales Q2Q%-26.12%
Revenue Next Year6.85%
Revenue Next 2Y-2.94%
Revenue Next 3Y-1.28%
Revenue Next 5Y-1.36%
EBIT growth 1Y-68.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.04%
EBIT Next 3Y-19.87%
EBIT Next 5YN/A
FCF growth 1Y-32.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.45%
OCF growth 3YN/A
OCF growth 5YN/A

KYMERA THERAPEUTICS INC / KYMR FAQ

Can you provide the ChartMill fundamental rating for KYMERA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to KYMR.


What is the valuation status of KYMERA THERAPEUTICS INC (KYMR) stock?

ChartMill assigns a valuation rating of 0 / 10 to KYMERA THERAPEUTICS INC (KYMR). This can be considered as Overvalued.


Can you provide the profitability details for KYMERA THERAPEUTICS INC?

KYMERA THERAPEUTICS INC (KYMR) has a profitability rating of 1 / 10.


What is the expected EPS growth for KYMERA THERAPEUTICS INC (KYMR) stock?

The Earnings per Share (EPS) of KYMERA THERAPEUTICS INC (KYMR) is expected to decline by -24.11% in the next year.